Venrock Adviser, LLC
Venrock Adviser, LLC reported 33 holdings worth US$3.3B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Venrock Adviser, LLC reported 33 holdings worth US$3.3B as of Jun 30, 2026. Largest: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Erasca, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 33
- Value as reported
- US$3.3B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Apogee Therapeutics, Inc. | 8.49M | US$1.13B | 34.2% |
| Oruka Therapeutics, Inc. | 4.15M | US$395M | 12.0% |
| Erasca, Inc. | 17.9M | US$328M | 9.9% |
| Spyre Therapeutics, Inc. | 2.99M | US$265M | 8.0% |
| Dianthus Therapeutics, Inc. | 1.18M | US$115M | 3.5% |
| Ocular Therapeutix, Inc. | 10.3M | US$102M | 3.1% |
| Damora Therapeutics, Inc. | 3.6M | US$93.7M | 2.8% |
| Savara, Inc. | 14.7M | US$90.8M | 2.8% |
| Jade Biosciences, Inc. | 3.22M | US$71.6M | 2.2% |
| Cogent Biosciences, Inc. | 1.64M | US$63.6M | 1.9% |
| Viridian Therapeutics, Inc. | 3.26M | US$59.8M | 1.8% |
| Vor Biopharma Inc. | 3.04M | US$56M | 1.7% |
| Dyne Therapeutics, Inc. | 2.17M | US$48.3M | 1.5% |
| Maze Therapeutics, Inc. | 1.6M | US$47.8M | 1.4% |
| Relmada Therapeutics, Inc. | 6.84M | US$47.4M | 1.4% |
| Oric Pharmaceuticals, Inc. | 4.32M | US$46.8M | 1.4% |
| Crescent Biopharma, Inc. | 2.13M | US$38.4M | 1.2% |
| Zura Bio Limited | 6.43M | US$38M | 1.2% |
| Enliven Therapeutics, Inc. | 526K | US$26.7M | 0.81% |
| Cybin, Inc. | 3.85M | US$25.5M | 0.77% |
| Cullinan Therapeutics, Inc. | 1.38M | US$25.1M | 0.76% |
| Century Therapeutics, Inc. | 8.7M | US$21.3M | 0.65% |
| Artiva Biotherapeutics, Inc. | 2.04M | US$19.8M | 0.60% |
| Cytomx Therapeutics, Inc. | 4.98M | US$18.7M | 0.57% |
| Achieve Life Sciences, Inc. | 2.75M | US$18M | 0.54% |
| Parabilis Medicines, Inc. | 625K | US$17.1M | 0.52% |
| Surrozen, Inc. | 633K | US$16.4M | 0.50% |
| Korro Bio, Inc. | 1.01M | US$13.3M | 0.40% |
| Alto Neuroscience, Inc. | 500K | US$13.2M | 0.40% |
| X4 Pharmaceuticals, Inc. | 1.93M | US$9.03M | 0.27% |
| Research Alliance Corporation Iii | 300K | US$3.21M | 0.10% |
| Inmed Pharmaceuticals Inc. | 32,685 | US$50,662 | <0.01% |
| Engene Holdings Inc. | 0 | US$0 | 0.00% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Septerna, Inc. | 0 | US$0 | 0.00% |
| Tenax Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related